Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Böblingen – page 69

944 clinical trials in Böblingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Böblingen at a glance
944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

944 trials in Böblingen

Open in trial search

Glioblastoma

Not recruiting

Study of Troriluzole and ADI-PEG-20 for Patients with Newly Diagnosed and Recurrent Glioblastoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elrelesertib
  • Sponsor:Global Coalition For Adaptive Research Inc.

Colour blindness

Not recruiting

Study on the Safety and Effectiveness of rAAV.hCNGA3 for Adults and Minors with CNGA3-Linked Achromatopsia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:rAAV.hCNGA3
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LT3001
  • Sponsor:Lumosa Therapeutics Co. Ltd.

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study Comparing Linvoseltamab to Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study on Apalutamide and Drug Combination for Patients with Metastatic Castration-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Deafness neurosensory

Not recruiting

Study on ACOU085 to Prevent Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ACOU085
  • Sponsor:Acousia Therapeutics GmbH

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Böblingen

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on multiple sclerosis treatments, including studies comparing new therapies like fenebrutinib and frexalimab with established treatments. Several trials are investigating novel approaches for both relapsing and primary progressive forms of MS.

  • Relapsing Multiple Sclerosis
  • Primary Progressive MS
  • Brain Inflammation

Additional studies explore innovative treatments for migraine prevention in patients who haven't responded to conventional therapies.

02 Mental Health Studies

Comprehensive research into major depressive disorder and schizophrenia, evaluating new therapeutic approaches. Trials include testing novel compounds for depression with anhedonia and long-term safety studies for schizophrenia treatments.

  • Depression Treatment
  • Schizophrenia Management
  • ADHD Therapy

Studies also examine new formulations for ADHD treatment in adults, comparing immediate and modified-release medications.

03 Oncology Research

Innovative trials in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate both neoadjuvant and adjuvant therapeutic approaches.

  • Triple-Negative Breast Cancer
  • HER2-Negative Breast Cancer
  • Rectal Cancer

Additional research examines treatment strategies for locally advanced rectal cancer, comparing pre- and post-surgical interventions.

04 Neurodegenerative Conditions

Critical research into Alzheimer's disease and related conditions, with studies focusing on treating associated symptoms like psychosis and agitation in dementia patients.

  • Alzheimer's Psychosis
  • Dementia Management
  • Behavioral Symptoms

These trials aim to improve quality of life for patients with neurodegenerative disorders through targeted symptom management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.